Axicabtagene ciloleucel (Yescarta®). HTA ID: 22066

Assessment Status Awaiting response from Applicant
HTA ID 22066
Drug Axicabtagene ciloleucel
Brand Yescarta®
Indication For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
Assessment Process
Rapid review commissioned 27/09/2022
Rapid review completed 10/11/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of axicabtagene ciloleucel compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 30/11/2022
Pre-submission consultation with Applicant 21/03/2023
Full submission received from Applicant 06/09/2023
Preliminary review sent to Applicant 01/03/2024